Swiftly Meds Private Limited

Mitant 50 mg Capsules (Sunitinib Malate)

Description:

Mitant 50 mg Capsules contain sunitinib malate, a tyrosine kinase inhibitor (TKI) used in the treatment of various types of cancer. Sunitinib is a multikinase inhibitor that works by blocking the activity of specific enzymes (known as tyrosine kinases) that promote the growth and spread of cancer cells. Sunitinib targets several important receptors involved in tumor growth, angiogenesis (the formation of new blood vessels), and tumor metastasis. It is specifically effective against cancers that rely on these mechanisms for their growth and spread.

Uses of Mitant 50 mg Capsules (Sunitinib Malate):

Sunitinib is used in the treatment of several different types of cancer, especially advanced and metastatic cancers that rely on angiogenesis for their growth. Some common uses include:

 

1. Renal Cell Carcinoma (RCC):

   • Sunitinib is approved for the treatment of advanced or metastatic renal cell carcinoma (RCC), a type of kidney cancer. It is used when surgery is not an option or when the disease has spread to other parts of the body.

2. Gastrointestinal Stromal Tumors (GISTs):

   • It is used to treat GISTs, a rare form of cancer that occurs in the stomach or intestines. Sunitinib is indicated when the disease is refractory to imatinib or when the tumors are unresectable (cannot be surgically removed).

3. Pancreatic Neuroendocrine Tumors (PNETs):

   • Sunitinib is used to treat pancreatic neuroendocrine tumors that are advanced or metastatic and are not amenable to surgical resection.

4. Other Potential Uses:

   • Sunitinib may be investigated in the treatment of other types of cancer and tumors that involve angiogenesis, although its primary indications are in RCC, GISTs, and PNETs.

Common Side Effects:

• Fatigue: A feeling of weakness or tiredness is one of the most common side effects of sunitinib therapy.

• Diarrhea: Sunitinib can cause gastrointestinal upset, including diarrhea.

• Skin Rash: Some individuals may develop a rash, especially on the hands and feet.

• Hypertension (High Blood Pressure): Sunitinib can cause elevated blood pressure, which needs to be monitored regularly.

• Nausea: Nausea can occur, often leading to loss of appetite and subsequent weight loss.

• Mouth Sores: Mucositis, or mouth sores, is common and can make eating and swallowing painful.

• Swelling (Edema): Swelling in the feet, hands, or other parts of the body is a frequent side effect.

Serious Side Effects:

• Cardiovascular Issues: Sunitinib can lead to heart failure, QT prolongation, and arrhythmias. Cardiac monitoring is important during treatment.

• Liver Toxicity: Liver function can be impacted by sunitinib, leading to elevated liver enzymes, jaundice, and more severe liver damage.

• Bone Marrow Suppression: Sunitinib can suppress bone marrow function, leading to low blood counts (neutropenia, anemia, thrombocytopenia). This increases the risk of infection, bleeding, and fatigue.

• Gastrointestinal Perforation: Rarely, sunitinib can lead to perforation (holes) in the gastrointestinal tract, which may require immediate medical attention.

Lenvat 10 mg Capsules: Product Description

Lenvat 10 mg capsules contain Lenvatinib, an oral medication used primarily for the treatment of various types of cancer, including differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. Lenvatinib belongs to a class of drugs called tyrosine kinase inhibitors, which work by blocking specific proteins that promote cancer cell growth. This inhibition helps slow down the spread of cancer cells and, in some cases, may reduce the size of tumors.

Indications and Uses: Lenvat 10 mg capsules are prescribed for:

1. Differentiated Thyroid Cancer (DTC): Used for patients with radioactive iodine-refractory differentiated thyroid cancer, to improve progression-free survival.
2. Renal Cell Carcinoma (RCC): In combination with everolimus, Lenvat helps treat advanced renal cell carcinoma.
3. Hepatocellular Carcinoma (HCC): For advanced liver cancer, it can be used in patients who have not received prior systemic therapy.

Lenvatinib targets the vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), and other tyrosine kinases involved in tumor growth, angiogenesis, and cancer cell survival.

Dosage and Administration:

• The typical starting dose for Lenvat is 10 mg once daily for adults.
• The medication should be taken at the same time every day, with or without food.
• The capsules should be swallowed whole and should not be chewed, divided, or crushed.
• Dosage adjustments may be required based on tolerance and specific side effects observed, as determined by a healthcare provider.

Side Effects: While Lenvat 10 mg is effective in treating certain cancers, it may cause side effects, including:

• Common Side Effects: Fatigue, loss of appetite, weight loss, nausea, diarrhea, and high blood pressure.
• Serious Side Effects: Liver damage, heart problems (including hypertension), gastrointestinal perforations, and bleeding complications. Regular monitoring of liver function and blood pressure is recommended during treatment.

Precautions: Before starting Lenvat 10 mg capsules, inform your doctor if you have a history of heart disease, high blood pressure, liver issues, or gastrointestinal problems. Pregnant or breastfeeding women should not use Lenvat, as it may harm the unborn child or infant. Lenvat should only be used under the supervision of a qualified healthcare provider who can monitor the patient's progress and manage any adverse effects.

Storage:

• Store the capsules at room temperature (15°C to 30°C).
• Keep the capsules in their original packaging to protect from moisture.
• Keep out of reach of children.

Conclusion: Lenvat 10 mg capsules are a vital option in the management of certain cancers, particularly in patients with advanced or metastatic disease. By blocking key enzymes that allow tumors to grow and spread, Lenvatinib provides an effective therapeutic approach to prolong survival and improve the quality of life for cancer patients. Always follow your healthcare provider’s instructions and report any side effects or concerns during treatment.

Lenva 4 mg Capsules contain lenvatinib, an oral medication used primarily to treat various types of cancer. Lenvatinib is a tyrosine kinase inhibitor (TKI), which means it works by blocking specific proteins that are involved in the growth of cancer cells.

Mechanism of Action:

Lenvatinib targets and inhibits several receptor tyrosine kinases involved in cancer cell growth, angiogenesis (the formation of new blood vessels), and tumor progression. Some of the main targets include:

• Vascular endothelial growth factor receptors (VEGFR)

• Fibroblast growth factor receptors (FGFR)

• Platelet-derived growth factor receptor (PDGFR)

• Ret receptor

By blocking these pathways, lenvatinib helps to reduce the blood supply to tumors and slows their growth or spread.

Indications:

Lenvatinib is used to treat various cancers, including:

• Thyroid cancer: Specifically used for differentiated thyroid cancer that is refractory to radioactive iodine therapy.

• Renal cell carcinoma (RCC): In combination with everolimus, it is used for advanced kidney cancer.

• Hepatocellular carcinoma (HCC): Lenvatinib is used as a treatment for liver cancer, typically when the disease is in an advanced stage or when patients are not candidates for surgery.

Dosage and Administration:

• Dosage: The exact dosage will depend on the specific cancer being treated and individual patient factors. For example:

  • Thyroid cancer: The typical starting dose for adults is 24 mg per day (taken as a single dose), but it can be adjusted based on side effects and the patient's tolerance.

  • Renal cell carcinoma and liver cancer: In combination with other treatments, the dosage can vary, but it is usually in the range of 18 mg per day.

• Administration: Lenva 4 mg capsules are taken orally, once daily, with or without food. Side Effects:

Common side effects of lenvatinib may include:

• Fatigue

• Hypertension (high blood pressure)

• Diarrhea

• Decreased appetite

• Weight loss

• Nausea

• Hand-foot syndrome (redness, swelling, or pain on the palms of the hands or soles of the feet)

Serious side effects (though rare) can include:

• Heart problems: Such as high blood pressure, heart failure, or arrhythmias.

• Liver toxicity: Including liver damage or elevated liver enzymes.

• Gastrointestinal perforations: A serious condition involving holes in the digestive tract.

• Proteinuria (high levels of protein in urine), which can indicate kidney damage.

Precautions:

Before taking lenvatinib, it's important to inform your healthcare provider if you have:

• Heart disease, especially high blood pressure or heart failure.

• Liver problems, as lenvatinib can affect liver function.

• Kidney problems, since lenvatinib can affect kidney function.

• Bleeding problems, as lenvatinib may increase the risk of bleeding.

• Proteinuria or changes in urine output.

Storage:

• Store Lenva (lenvatinib) capsules at room temperature, away from heat, moisture, and direct light (ideally between 20°C to 25°C or 68°F to 77°F).

Lenced Lenvatinib 4 mg Tablets contain lenvatinib, a tyrosine kinase inhibitor (TKI) that is used in the treatment of certain types of cancer. Lenvatinib works by inhibiting multiple tyrosine kinase receptors involved in the growth and spread of cancer cells, thus slowing or halting the progression of tumors.

Mechanism of Action:

Lenvatinib targets several receptor tyrosine kinases, including:

• Vascular Endothelial Growth Factor Receptors (VEGFR)

• Fibroblast Growth Factor Receptors (FGFR)

• Platelet-Derived Growth Factor Receptors (PDGFR)

• Rearranged during Transfection (RET) Receptors

By blocking these receptors, Lenced (lenvatinib) reduces blood supply to tumors and prevents the formation of new blood vessels that tumors need to grow and spread.

Indications:

Lenced Lenvatinib 4 mg Tablets are primarily used for the treatment of:

• Differentiated Thyroid Cancer (DTC): For patients with advanced or metastatic thyroid cancer that is resistant to radioactive iodine therapy.

• Renal Cell Carcinoma (RCC): In combination with everolimus for advanced kidney cancer.

• Hepatocellular Carcinoma (HCC): For liver cancer, especially in patients who are not candidates for surgery or liver transplant.

Dosage and Administration:

• Dosage: The typical dose of Lenced (lenvatinib) depends on the type of cancer being treated:

  • Differentiated Thyroid Cancer (DTC): The usual starting dose is 24 mg per day.

  • Renal Cell Carcinoma (RCC) and Hepatocellular Carcinoma (HCC): The usual dose is 18 mg per day in combination with everolimus.

  Lenced 4 mg Tablets should be taken once daily, with or without food. The tablets should be swallowed whole with a glass of water. It is important to follow your doctor’s instructions regarding the dosage.

  If a dose is missed, take it as soon as you remember unless it’s almost time for your next dose. Do not double the dose to make up for a missed one.

Side Effects:

Common side effects of Lenced (lenvatinib) include:

• Fatigue

• Hypertension (high blood pressure)

• Diarrhea

• Decreased appetite

• Weight loss

• Hand-foot syndrome (pain, redness, or swelling in the hands and feet)

• Nausea

• Mouth sores (stomatitis)

Serious side effects may include:

• Heart issues: Including arrhythmias (irregular heartbeats), heart failure, or high blood pressure.

• Liver toxicity: Elevated liver enzymes or liver damage.

• Gastrointestinal perforations: Rare but serious holes or tears in the digestive tract.

• Severe bleeding or clotting issues.

• Proteinuria (high levels of protein in urine), which may indicate kidney damage.
  
  

Storage:

• Store Lenced 4 mg Tablets at room temperature, between 20°C to 25°C (68°F to 77°F).

• Keep the tablets in their original container and away from moisture, heat, and direct sunlight.

• Keep out of reach of children.

Hertraz 440 mg Trastuzumab Injection – Description

Composition: Hertraz 440 mg Trastuzumab Injection is a monoclonal antibody, which contains trastuzumab as its active ingredient. Each vial contains 440 mg of trastuzumab in 20 mL of solution, providing a concentration of 22 mg/mL. The formulation also includes excipients such as histidine, histidine hydrochloride monohydrate, polysorbate 20, water for injection, and other stabilizing agents. 

Indications: Hertraz 440 mg Trastuzumab Injection is indicated for the treatment of:

• HER2-positive breast cancer: Used in both adjuvant and metastatic settings for the treatment of HER2-positive breast cancer. This includes early breast cancer, metastatic breast cancer (MBC), and locally advanced breast cancer.

• HER2-positive gastric cancer: For the treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with chemotherapy.

Dosage and Administration: The recommended dose of Hertraz for breast cancer treatment in patients without prior chemotherapy for metastatic disease is an initial loading dose of 8 mg/kg body weight, followed by 6 mg/kg body weight every three weeks. For gastric cancer, Hertraz is administered as an initial dose of 8 mg/kg, followed by 6 mg/kg every three weeks, in combination with chemotherapy regimens.

The drug is administered intravenously, and infusion rates should be adjusted based on the patient's response and any adverse reactions. The injection should be given under the supervision of a qualified healthcare professional.

Contraindications: Hertraz should not be used in patients who have known hypersensitivity to trastuzumab or any of the excipients of the formulation. It is also contraindicated in patients with severe heart failure or significant cardiac dysfunction due to the potential risk of cardiotoxicity associated with trastuzumab therapy.

Warnings and Precautions:

• Cardiac Function: Trastuzumab therapy is associated with the potential for heart-related issues, including decreased left ventricular ejection fraction (LVEF) and heart failure. Cardiac function should be monitored regularly.

• Infusion Reactions: Some patients may experience infusion-related reactions (IRRs), including fever, chills, nausea, vomiting, and shortness of breath. These reactions are more common with the first infusion.

• Pregnancy and Lactation: Trastuzumab may harm the fetus and should not be used during pregnancy unless the potential benefit justifies the risk to the fetus. It is not recommended for use in breastfeeding women.

Adverse Effects: Common side effects of Hertraz include:

• Fever, chills, and fatigue

• Nausea and vomiting

• Headache

• Infusion-related reactions

• Diarrhea

• Cardiac toxicity (including heart failure)

Storage: Hertraz should be stored in a refrigerator at 2–8°C (36–46°F). Do not freeze. The product should be protected from light and should not be used after the expiration date printed on the vial.

Vivitra 150mg Injection – Description

Vivitra 150mg Injection is a pharmaceutical product used in the treatment of various medical conditions, specifically in the context of HIV-1 infection and other viral infections. The active ingredient in Vivitra is Rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which works by inhibiting the reverse transcriptase enzyme necessary for HIV replication.

Composition:
Each 1ml of Vivitra 150mg injection contains:

• Rilpivirine 150 mg as the active ingredient.

• Other excipients to aid in the formulation.

Mechanism of Action:
Rilpivirine, the active component, is a potent NNRTI. It selectively binds to the reverse transcriptase enzyme, preventing the conversion of HIV RNA into DNA. This action inhibits the replication of HIV-1, reducing the viral load in the body and helping in the management of HIV infection.

Indications:
Vivitra 150mg Injection is primarily indicated for:

• The treatment of HIV-1 infection in adult patients who are HIV-1 positive and have no history of treatment failure or known mutations associated with resistance to rilpivirine.

• It is often used in combination with other antiretroviral agents as part of an antiretroviral therapy (ART) regimen to manage HIV infection.

Dosage and Administration:

• Adult dose: The recommended dose of Vivitra 150mg Injection is 150 mg administered intramuscularly once every 4 weeks by a healthcare professional. The injection is generally administered into the buttocks. It should be administered by a qualified medical provider to ensure the correct technique and monitoring.

• Adjustment: Dosage adjustments may be needed based on patient-specific factors like renal or hepatic impairment.

Side Effects:
Common side effects may include:

• Injection site reactions (pain, redness, or swelling).

• Headache, dizziness, or fatigue.

• Gastrointestinal issues, such as nausea and diarrhea.

• Skin rashes or hypersensitivity reactions in some cases.

Serious side effects, though rare, can include:

• Severe allergic reactions.

• Liver problems (yellowing of the skin/eyes, dark urine, etc.).

• Depression or mood changes.

Contraindications:
Vivitra is contraindicated in patients with:

• Known hypersensitivity to rilpivirine or any component of the injection.

• Severe hepatic impairment.

Precautions:

• Caution is advised in patients with moderate liver impairment or those with a history of psychiatric conditions.

• Rilpivirine should not be used with certain medications that may reduce its efficacy or increase the risk of serious side effects.

Storage:
Vivitra should be stored in a cool, dry place at a temperature not exceeding 30°C. Keep it out of the reach of children and avoid freezing the product.

Conclusion:
Vivitra 150mg Injection is an effective medication for managing HIV-1 infection, particularly when combined with other antiretroviral therapies. Patients must be monitored regularly to evaluate treatment effectiveness and potential side effects. Always consult a healthcare provider before starting or altering the treatment regimen with Vivitra.

Cazanat 60mg Tablets (Cabozantinib)

Description: Cazanat 60mg Tablets contain Cabozantinib, a tyrosine kinase inhibitor (TKI) used for the treatment of certain types of cancer. Cabozantinib works by blocking specific proteins known as receptor tyrosine kinases that are involved in the growth and spread of cancer cells. It also inhibits the formation of new blood vessels that tumors require to grow (angiogenesis). By interfering with these processes, Cabozantinib helps slow tumor growth and the spread of cancer to other parts of the body.

Indications:

• Renal Cell Carcinoma (RCC): Cabozantinib is used to treat advanced or metastatic renal cell carcinoma (kidney cancer), either alone or in combination with other cancer treatments.

• Hepatocellular Carcinoma (HCC): It is also used for the treatment of advanced liver cancer (hepatocellular carcinoma), especially in patients who have been previously treated or are ineligible for other therapies.

• Medullary Thyroid Cancer (MTC): In some cases, Cabozantinib is used to treat medullary thyroid cancer, a type of thyroid cancer that is resistant to many other therapies.

• Other Cancers: It may also be used for treating other types of cancer based on physician discretion and specific protocols.

Mechanism of Action: Cabozantinib is a multi-targeted tyrosine kinase inhibitor. It works by inhibiting several key enzymes involved in cancer growth and the development of new blood vessels that tumors need to survive. Specifically, Cabozantinib targets the MET, VEGFR2, and AXL receptors, which are responsible for promoting tumor growth, metastasis, and angiogenesis. By blocking these receptors, Cabozantinib helps to slow or halt the growth and spread of tumors.

Dosage:

• Starting dose: The typical starting dose for Cazanat 60mg Tablets is 60 mg once daily. The dose may be adjusted based on individual patient needs and side effects.

• Administration: Cabozantinib should be taken once a day, ideally at the same time each day, and can be taken with or without food.

• Swallow the tablet whole: Do not chew, crush, or break the tablet. Take it with a full glass of water.

• Missed dose: If you miss a dose, take it as soon as you remember, unless it’s almost time for your next dose. Do not double the dose to make up for a missed dose.

Side Effects: Common side effects of Cabozantinib include:

• Diarrhea

• Fatigue or weakness

• Loss of appetite

• Nausea and vomiting

• High blood pressure (hypertension)

• Weight loss

• Hand-foot syndrome (redness, pain, or peeling of the skin on the hands and feet)

• Mouth sores

Cazanat 40 mg is a medication primarily used to treat erectile dysfunction (ED) in men. The active ingredient in Cazanat is Tadalafil, a PDE5 inhibitor that enhances blood flow to the penis during sexual stimulation, helping men achieve and maintain an erection. Cazanat is also used in the treatment of benign prostatic hyperplasia (BPH) and pulmonary arterial hypertension (PAH) in certain patients.

Dosage and Administration: Cazanat 40 mg tablets should be taken orally with or without food. For the treatment of ED, it is typically recommended to take one tablet approximately 30 minutes before sexual activity. The tablet should be swallowed whole with water.

Cazanat can also be taken on a daily basis (lower doses may be prescribed for daily use), but typically, the 40 mg dosage is used for occasional use as needed. The effect can last up to 36 hours, providing greater flexibility for sexual activity compared to other ED treatments. Do not exceed one tablet within 24 hours.

How it Works: The active ingredient, Tadalafil, works by inhibiting the enzyme PDE5, which regulates the blood flow in the penis. By blocking this enzyme, Tadalafil helps increase the levels of cGMP (cyclic guanosine monophosphate), which relaxes the smooth muscles in the blood vessels, allowing increased blood flow to the penis. This results in improved erectile function when combined with sexual arousal.

Indications:

• Erectile Dysfunction (ED): Cazanat 40 mg is prescribed to men who are unable to achieve or maintain an erection suitable for sexual intercourse.

• Benign Prostatic Hyperplasia (BPH): Cazanat is used to relieve symptoms of BPH, such as difficulty urinating, in men with an enlarged prostate.

• Pulmonary Arterial Hypertension (PAH): In some cases, Cazanat may be used to treat PAH, a condition that involves high blood pressure in the lungs.

Precautions and Warnings:

• Consult with a doctor before using Cazanat, especially if you have a history of heart disease, kidney problems, or liver disorders.

• Avoid using Cazanat if you are taking any form of nitrate medications (used for chest pain), as this may cause a dangerous drop in blood pressure.

• Patients who have had a heart attack, stroke, or severe heart conditions should consult their doctor before taking Cazanat.

• Do not use Cazanat if you have hypotension (low blood pressure), or if you are allergic to Tadalafil or any other ingredient in the product.

• Side Effects: Common side effects may include headaches, dizziness, back pain, muscle aches, nasal congestion, or flushing. These side effects are usually mild and temporary. Seek medical help if you experience prolonged side effects.

• Priapism: Seek immediate medical attention if you have an erection lasting longer than 4 hours, as this may cause permanent damage to the penis.

• Drug Interactions: Be sure to inform your doctor about any other medications you are taking, as certain drugs (such as alpha-blockers or antifungal treatments) may interact with Tadalafil.

Storage: Store Cazanat 40 mg tablets in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Conclusion: Cazanat 40 mg is an effective treatment for erectile dysfunction, providing long-lasting results that help men regain confidence in their sexual health. When used responsibly and under medical supervision, it can improve sexual performance and overall quality of life. Always follow your healthcare provider's instructions to ensure safe and effective use.

Fulviglen 250 mg Injection (Fulvestrant)

Generic Name: Fulvestrant
Brand Name: Fulviglen
Strength: 250 mg per injection

Description:

Fulviglen is a brand name for the injectable formulation of fulvestrant, a type of hormone therapy used in the treatment of certain types of breast cancer. Fulvestrant is an estrogen receptor antagonist that works by blocking and degrading the estrogen receptor on breast cancer cells. Estrogen promotes the growth of many breast cancers, so by blocking the estrogen receptors, fulvestrant helps to prevent cancer cell growth and spread.

Fulvestrant is primarily used in:

• Hormone receptor-positive breast cancer in women who have gone through menopause.

• Metastatic breast cancer: It is often used in combination with other treatments when the cancer has spread or recurred after previous therapies, especially in patients who have previously received tamoxifen or other aromatase inhibitors.

Indications:

• Breast Cancer (Hormone Receptor-Positive): For the treatment of locally advanced or metastatic breast cancer in postmenopausal women, either as a monotherapy or in combination with other medications (e.g., a CDK4/6 inhibitor).

• Metastatic Breast Cancer: After progression on previous anti-estrogen therapies like tamoxifen or aromatase inhibitors.

Mechanism of Action:

Fulvestrant works by:

• Binding to estrogen receptors on cancer cells, which prevents estrogen from binding and stimulating the growth of cancer cells.

• Inducing degradation of the estrogen receptor, leading to a reduction in estrogen receptor levels inside cancer cells.

Dosage and Administration:

• Dose: The usual dose of Fulviglen is 250 mg administered as an intramuscular injection, typically given every two weeks for the first three months, and then once a month thereafter.

• The injection is typically given into the gluteal (buttock) muscle by a healthcare provider.

• Treatment schedules may vary based on individual patient conditions, so it's essential to follow the specific instructions from the healthcare provider.

Side Effects:

Common side effects of Fulviglen include:

• Pain at the injection site

• Fatigue

• Hot flashes

• Nausea

• Headache

• Joint pain

• Muscle pain

Serious side effects that require immediate medical attention include:

• Severe allergic reactions (e.g., difficulty breathing, swelling of the face or throat)

• Liver problems (yellowing of the skin or eyes, dark urine, persistent nausea or vomiting)

• Blood clots or deep vein thrombosis (pain, swelling, or redness in the legs)

• Severe bone pain or fractures

Storage:

• Storage Conditions: Store Fulviglen refrigerated between 2°C to 8°C (36°F to 46°F).

• Do not freeze.

• Keep the vial in the outer carton to protect it from light.

• If the vial has been stored at room temperature, it should be used within 30 days.

Administration: Fulvestrant should only be administered by a qualified healthcare provider, as it is an injection.

Palbinas 125 mg Capsules (Palbociclib)

Description: Palbinas is a brand name for palbociclib, an oral targeted therapy drug used primarily in the treatment of certain types of breast cancer. Specifically, it is used in combination with other medications, such as letrozole or anastrozole, in the treatment of hormone receptor-positive (HR-positive), HER2-negative breast cancer. This includes both early-stage and metastatic or advanced breast cancer.

Uses of Palbinas (Palbociclib) 125 mg Capsules:

 

1. HR-Positive, HER2-Negative Breast Cancer:

   • Metastatic Breast Cancer: Palbinas is used in combination with letrozole or anastrozole for the treatment of metastatic hormone receptor-positive, HER2-negative breast cancer in postmenopausal women.

   • Early-Stage Breast Cancer: It is also used in combination with letrozole for the treatment of early-stage HR-positive, HER2-negative breast cancer to reduce the risk of recurrence.

   • Advanced or Relapsed Breast Cancer: For patients with advanced or relapsed breast cancer, palbociclib is used as part of combination therapy to manage disease progression.

1. Common Side Effects:

   • Neutropenia (Low White Blood Cell Count): This is one of the most common side effects of palbociclib. A low white blood cell count increases the risk of infections.

   • Fatigue: Many patients experience fatigue, which can range from mild to severe and affect daily activities.

   • Diarrhea: Palbociclib can cause gastrointestinal issues, including diarrhea, which may be mild to moderate in severity.

   • Nausea: Some patients may experience nausea, which can be mild to moderate.

   • Loss of Appetite: A reduced appetite is common and may lead to weight loss in some patients.

   • Hair Thinning or Hair Loss: Some people may experience hair thinning or temporary hair loss during treatment.

   • Mouth Sores (Stomatitis): Ulcers or sores in the mouth may occur, causing discomfort.

2. Serious Side Effects:

   • Infections: Due to neutropenia, the immune system is weakened, and patients may be at a higher risk for infections. Symptoms such as fever, chills, or severe sore throat should be reported immediately.

   • Severe Neutropenia: Very low white blood cell counts can lead to life-threatening infections. Regular blood tests are required to monitor for this condition.

   • Lung Issues: Pneumonitis or inflammation of the lungs can occur, leading to symptoms like persistent cough, difficulty breathing, and chest pain. If these symptoms develop, patients should seek medical attention immediately.

   • Liver Toxicity: Palbociclib can cause liver problems. Symptoms of liver issues include yellowing of the skin or eyes (jaundice), dark urine, and pain in the upper abdomen.

   • Blood Clots: There is an increased risk of blood clots in patients on palbociclib. Symptoms such as swelling in the legs, chest pain, or shortness of breath should be reported immediately.

Abiratas 250 mg Tablet Description

Brand Name: Abiratas
Generic Name: Abiraterone Acetate
Strength: 250 mg
Dosage Form: Tablet

Introduction: Abiratas 250 mg Tablet contains Abiraterone Acetate, a medication primarily used in the treatment of prostate cancer. It is an androgen biosynthesis inhibitor that works by reducing the production of testosterone, a hormone that can fuel the growth of prostate cancer cells. Abiraterone Acetate is often prescribed for metastatic castration-resistant prostate cancer (mCRPC), particularly in combination with prednisone or prednisolone.

Indications:

• Metastatic Castration-Resistant Prostate Cancer (mCRPC): Abiratas is indicated for the treatment of men with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.
• High-Risk Prostate Cancer: It may be used in combination with prednisone for the treatment of high-risk localized or advanced prostate cancer, following initial therapy.

Dosage and Administration: The recommended dosage of Abiratas 250 mg is one tablet daily. It is typically taken orally, in combination with prednisone (usually 5 mg twice daily). The tablet should be swallowed whole with water and can be taken with or without food. Patients should not take more than the prescribed dose. It is essential to follow the dosing schedule provided by the healthcare provider to achieve optimal results.

Precautions:

• Liver Function: Abiraterone can cause liver problems, including hepatotoxicity. Liver function tests should be monitored regularly.
• Mineralocorticoid Excess: Due to its mechanism of action, Abiraterone can increase the production of mineralocorticoids, leading to hypertension, hypokalemia, and fluid retention. Patients should be closely monitored for these side effects, and antihypertensive therapy may be required.
• Pregnancy and Lactation: Abiraterone should not be used during pregnancy or breastfeeding as it may harm the fetus or infant.
• Adrenal Insufficiency: Abiraterone can cause adrenal insufficiency, particularly when used without proper dosing of corticosteroids like prednisone. Monitoring for symptoms of adrenal insufficiency, such as fatigue, dizziness, and weakness, is essential.

Side Effects: Common side effects associated with Abiratas 250 mg Tablet include:

• Fatigue
• Hot flashes
• Joint pain or swelling
• Diarrhea
• Nausea
• Increased blood pressure
• Fluid retention (edema)
• Elevated liver enzymes
• Changes in potassium levels

Contraindications:

• Abiraterone is contraindicated in patients with severe liver impairment (Child-Pugh class C).
• Hypersensitivity to abiraterone or any of its components.

Drug Interactions:

• Corticosteroids: Abiraterone is often used in conjunction with corticosteroids like prednisone. The combination is essential to manage side effects related to cortisol production.
• Antifungals & Antibiotics: Drugs such as ketoconazole or rifampicin can interact with Abiraterone, altering its metabolism. Dose adjustments may be needed.
• Anticoagulants: Patients taking warfarin or other anticoagulants may need regular monitoring of their INR (International Normalized Ratio) due to potential drug interactions.

Storage:

• Store at room temperature, away from heat and moisture.
• Keep out of the reach of children.
• Do not use the medicine after its expiration date.

Palnat 125 mg Capsules - Description

Brand Name: Palnat
Generic Name: Palbociclib
Strength: 125 mg
Formulation: Capsules

Indications: Palnat 125 mg capsules contain Palbociclib, a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), primarily used in the treatment of hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer. It is often prescribed in combination with other treatments, such as aromatase inhibitors or letrozole, for metastatic or advanced breast cancer in adult women and men who are candidates for systemic therapy.

Mechanism of Action: Palbociclib, the active ingredient in Palnat, works by inhibiting the activity of CDK4 and CDK6. These proteins are involved in the regulation of the cell cycle, and their overactivation can lead to uncontrolled cancer cell division and growth. By blocking CDK4/6, Palbociclib prevents the progression of the cell cycle, particularly from the G1 to the S phase, which is critical for DNA synthesis and cell division. This helps slow down or stop the growth of cancer cells.

Dosage and Administration:

• The recommended dosage of Palnat (Palbociclib) is 125 mg once daily, taken orally for 21 consecutive days of a 28-day cycle.
• The capsules should be swallowed whole with food and should not be crushed or chewed.
• It is typically taken in combination with an aromatase inhibitor, such as letrozole, for initial therapy or with letrozole for combination treatment in cases of breast cancer.

Side Effects: Common side effects of Palnat 125 mg capsules include:

• Neutropenia (low white blood cell count), which may increase the risk of infection.
• Fatigue and nausea.
• Diarrhea, which can often be managed with medication.
• Mouth sores and hair thinning.
• Increased liver enzymes, which should be monitored during treatment.

More serious but less common side effects may include:

• Pneumonitis (lung inflammation).
• Severe allergic reactions, such as rash, itching, or difficulty breathing.
• Blood clots and deep vein thrombosis.

Patients are advised to undergo regular blood tests, including liver function tests, during treatment.

Precautions and Warnings:

• Pregnancy and breastfeeding: Palnat should not be used during pregnancy, as it can harm a developing fetus. Women of childbearing age should use effective contraception during treatment. It is not known whether Palbociclib passes into breast milk, so breastfeeding should be avoided.
• Liver issues: Patients with pre-existing liver conditions should be monitored closely, as Palbociclib may elevate liver enzymes.
• Infection risk: Due to the potential for low white blood cell counts, Palnat can increase the risk of infections. Patients should report any signs of infection immediately.
• Drug interactions: Palbociclib may interact with other medications, including those that affect liver enzymes. Always inform your doctor about other medicines you are taking.

Storage: Palnat capsules should be stored in a cool, dry place at room temperature, away from moisture and heat. Keep out of reach of children.

Conclusion: Palnat 125 mg capsules represent a targeted treatment for HR-positive, HER2-negative breast cancer, offering a crucial therapeutic option for patients who need advanced or metastatic cancer care. As with all cancer therapies, treatment with Palnat should be managed by a qualified oncologist to ensure safety and effectiveness, along with appropriate monitoring for side effects.

Ramiven 150 mg Tablets - Product Description

Brand Name: Ramiven
Generic Name: Ramipril
Strength: 150 mg
Dosage Form: Tablet

Composition:
Each Ramiven tablet contains 150 mg of Ramipril as the active ingredient.

Introduction:
Ramiven 150 mg tablets are a prescription medication that belong to a class of drugs called ACE inhibitors (Angiotensin-Converting Enzyme inhibitors). ACE inhibitors are primarily used to treat high blood pressure (hypertension), heart failure, chronic kidney disease, and to reduce the risk of stroke and heart attacks.

Indications:
Ramiven 150 mg tablets are commonly prescribed for:

• Hypertension (High Blood Pressure): Helps in reducing elevated blood pressure and prevents complications like stroke, heart failure, and kidney disease.
• Heart Failure: Assists in the management of heart failure by improving heart function and reducing the heart's workload.
• Chronic Kidney Disease (CKD): Ramiven can help protect kidney function, especially in diabetic patients with kidney disease.
• Post-Myocardial Infarction: After a heart attack, Ramiven can help prevent the recurrence of cardiac events.
• Diabetic Nephropathy: Reduces protein leakage from the kidneys in diabetic patients, thus slowing down kidney damage.

Mechanism of Action:
Ramiven works by inhibiting the enzyme ACE, which is responsible for converting angiotensin I into angiotensin II, a substance that causes blood vessels to constrict. By reducing the production of angiotensin II, Ramiven helps relax blood vessels, reducing blood pressure and the strain on the heart.

Dosage and Administration:

• Hypertension: Typically, the starting dose for adults is 2.5 mg to 5 mg once daily. The dose can be gradually increased depending on the patient’s response. For patients with high blood pressure, a maximum dose of 10 mg once daily is usually effective.
• Heart Failure: The starting dose is often lower (1.25 mg to 2.5 mg), and it is gradually increased.
• Post-Heart Attack: Initial doses generally begin at 2.5 mg to 5 mg daily, increasing to 10 mg once daily, based on tolerance.
• Chronic Kidney Disease or Diabetic Nephropathy: Dosage adjustments may be necessary depending on the individual’s condition and kidney function.

Precautions and Warnings:

• Kidney Function: Regular monitoring of kidney function is essential, particularly for patients with pre-existing kidney conditions or those who are on medications that can affect kidney function.
• Pregnancy and Breastfeeding: Ramiven is not recommended during pregnancy, especially in the second and third trimesters, as it can harm the fetus. It is also excreted in breast milk, so use during breastfeeding is generally advised against.
• Angioedema: Some patients may experience swelling of the face, lips, throat, or extremities. If you experience difficulty breathing or swallowing, seek immediate medical attention.
• Electrolyte Imbalance: The use of Ramiven may cause a rise in potassium levels (hyperkalemia), so patients need to be monitored for changes in blood potassium levels.
• Liver Function: Caution is advised for patients with liver problems, as the drug may require dose adjustments.

Side Effects:
Common side effects of Ramiven may include:

• Dizziness or lightheadedness
• Fatigue
• Dry cough
• Headache
• Elevated blood potassium levels (hyperkalemia)
• Nausea or vomiting

Storage:
Store at room temperature, away from direct light and moisture. Keep out of reach of children.

Lenome 25 mg Capsules - Description

Brand Name: Lenome
Generic Name: Mirtazapine
Strength: 25 mg per capsule
Dosage Form: Capsule
Therapeutic Class: Antidepressant (Atypical)

Indication:
Lenome 25 mg capsules are primarily used in the treatment of major depressive disorder (MDD) in adults. It may also be prescribed for generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and other mood-related conditions as determined by a healthcare provider.

Mechanism of Action:
Lenome contains Mirtazapine, an atypical antidepressant that works by modulating neurotransmitters in the brain, specifically serotonin and norepinephrine. Mirtazapine increases the levels of these chemicals, which are believed to have a good influence on mood, emotional well-being, and mental balance. It is also thought to affect certain receptors involved in the regulation of sleep, appetite, and anxiety.

Dosage and Administration:
The usual starting dose of Lenome is 15 mg once daily, taken preferably at bedtime due to its sedative properties. Depending on the individual’s response, the dose may be adjusted to 30 mg or 45 mg per day, but it is important that dosage adjustments only be made under the supervision of a healthcare provider. The capsules should be swallowed whole with a glass of water and may be taken with or without food.

Common Side Effects:
Some common side effects of Lenome 25 mg capsules include:

• Drowsiness or sedation
• Increased appetite and weight gain
• Dry mouth
• Dizziness
• Constipation
• Fatigue

Serious Side Effects:
Although rare, Lenome may cause serious side effects, including:

• Suicidal thoughts or behavior (especially in young adults)
• Severe allergic reactions (e.g., rash, swelling, difficulty breathing)
• Blood disorders such as agranulocytosis (low white blood cell count)
• Liver problems (yellowing of the skin or eyes)
• Seizures

If any of these symptoms occur, it is crucial to seek immediate medical attention.

Warnings and Precautions:

• Suicidality: Antidepressants, including Lenome, may increase the risk of suicidal thoughts or actions in children, adolescents, and young adults. Close monitoring by a healthcare provider is necessary during treatment initiation or dose changes.
• Elderly: Older adults may be more sensitive to the sedative effects and other side effects of Lenome.
• Drug Interactions: Lenome may interact with other medications, including monoamine oxidase inhibitors (MAOIs), central nervous system depressants, or other antidepressants. Always inform the healthcare provider about all medications being taken.
• Pregnancy and Lactation: Mirtazapine should only be used during pregnancy if the potential benefits justify the risks. It is excreted in breast milk, so caution is advised when nursing.

Storage:
Store Lenome 25 mg capsules in a cool, dry place, away from direct sunlight and moisture. Keep the medication out of the reach of children.

Conclusion:
Lenome 25 mg capsules offer a useful treatment for individuals suffering from major depressive disorder, anxiety, and other mood disorders. While it can be highly effective, careful attention to dosage, side effects, and interactions with other medications is essential for safety and optimal results. Always follow the guidance of a healthcare provider when using this medication.

Paleno 125 mg Capsules – Product Description

Brand Name: Paleno
Generic Name: Paliperidone
Strength: 125 mg per capsule
Dosage Form: Capsule, Oral

Introduction:
Paleno 125 mg Capsules are a prescription medication primarily used to treat mental health conditions such as schizophrenia and schizoaffective disorder. The active ingredient, Paliperidone, is an atypical antipsychotic that works by affecting the balance of certain neurotransmitters in the brain, particularly dopamine and serotonin. These neurotransmitters play key roles in mood, thinking, and behavior regulation, and by regulating them, Paleno helps manage symptoms such as delusions, hallucinations, and disorganized thinking.

Indications and Usage:

• Schizophrenia: Paleno is indicated for the treatment of schizophrenia in adults and adolescents aged 12 years and older. It is used to help alleviate symptoms like hallucinations, delusions, and cognitive disturbances.

• Schizoaffective Disorder: It is also prescribed for schizoaffective disorder, a condition characterized by symptoms of both schizophrenia and mood disorder, such as depression or mania.

• Other Uses: Paleno may be used off-label for various psychiatric conditions, as determined by a healthcare provider.

Dosage and Administration:
The dosage of Paleno 125 mg is individualized based on the patient's medical condition and response to treatment. Typically, the starting dose for schizophrenia in adults is 6 mg per day, and the dose can be gradually adjusted to achieve optimal therapeutic effects. The 125 mg strength is typically used as a maintenance dose, with the goal of minimizing symptoms while avoiding side effects.

Important Considerations:

• Administration: Paleno capsules should be taken orally, usually once a day with or without food. It is important to swallow the capsule whole and not chew or crush it.

• Missed Dose: If a dose is missed, it should be taken as soon as remembered, but if it’s almost time for the next dose, skip the missed dose to avoid taking two doses too close together.

• Alcohol and Drug Interactions: Alcohol should be avoided while taking Paleno, as it may increase side effects such as dizziness or drowsiness. Additionally, certain drugs, including those that affect liver enzymes, may alter the effectiveness of Paleno or increase the risk of side effects. Always inform the doctor about any other medications being taken.

Side Effects:
Common side effects of Paleno 125 mg may include:

• Drowsiness or sedation

• Weight gain

• Increased blood sugar levels

• Dizziness or lightheadedness

• Dry mouth

• Constipation

Patients should promptly inform their healthcare provider if they experience any of these serious side effects.

Precautions and Warnings:

• Pre-existing Conditions: Patients with a history of heart problems, liver or kidney issues, or seizures should inform their doctor before starting Paleno.

• Pregnancy and Breastfeeding: It is important to inform the healthcare provider if the patient is pregnant, planning to become pregnant, or breastfeeding. The safety of Paleno during pregnancy and lactation has not been fully established, and it should only be used if the benefits outweigh the risks.

• Elderly Patients: Older adults may be more sensitive to the side effects of Paleno, especially the risk of sedation and heart problems. Dosage adjustments may be necessary.

Endace 160 mg Tablets

Description: Endace 160 mg Tablets contain the active ingredient dabigatran etexilate mesylate, which is a direct oral anticoagulant (DOAC) used primarily to prevent and treat blood clots. Dabigatran works by inhibiting thrombin, a key enzyme in the blood clotting process, thereby reducing the risk of blood clots forming in the body. This medication is typically prescribed to reduce the likelihood of stroke and blood clots in patients with atrial fibrillation (AF) and to treat deep vein thrombosis (DVT) or pulmonary embolism (PE).

Endace is highly effective in preventing thrombotic events, which are caused by abnormal blood clot formation. It works without the need for routine blood monitoring, unlike some other blood thinners. The tablet is designed for oral administration and should be taken as prescribed by your healthcare provider.

Indications: Endace 160 mg Tablets are commonly prescribed for:

• Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

• Treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).

• Reducing the risk of DVT and PE in patients undergoing hip or knee replacement surgery.

Dosage and Administration: The standard dosage of Endace for adults with atrial fibrillation or other indications is typically 160 mg once daily, though the exact dosage will depend on individual factors such as kidney function, body weight, and the presence of other medical conditions. It is important to take Endace exactly as prescribed. The tablet should be swallowed whole, without breaking, chewing, or crushing it, and can be taken with or without food.

Side Effects: Like all medications, Endace may cause side effects, although not everyone will experience them. Common side effects include:

• Bleeding complications (such as nosebleeds, bruising, or abnormal bleeding).

• Upset stomach or gastrointestinal discomfort.

• Diarrhea, indigestion, or abdominal pain.

Serious but rare side effects include:

• Severe bleeding (e.g., prolonged or heavy bleeding, blood in urine or stool).

• Allergic reactions (such as rash, itching, or swelling).

If any signs of severe bleeding or allergic reactions occur, immediate medical attention should be sought.

Contraindications: Endace should not be used in individuals who have:

• Active bleeding disorders or have a history of major bleeding.

• Severe liver impairment or liver disease.

• Hypersensitivity to dabigatran etexilate or any of the excipients in the formulation.

• A mechanical heart valve.

It is also important to inform your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding.

Precautions:

• Regular monitoring is not required, but kidney function should be checked prior to starting treatment and periodically thereafter.

• Caution is advised in patients with renal impairment, as dose adjustments may be necessary.

• Co-administration with certain medications, particularly those that affect blood clotting or liver enzymes, may require dose adjustments or closer monitoring.

Storage: Endace Tablets should be stored in a cool, dry place, away from direct sunlight and out of the reach of children. Do not use the medication after the expiry date printed on the packaging.

Abevmy Bevacizumab 400 mg Injection – Description

Abevmy (Bevacizumab) 400 mg injection is a monoclonal antibody that is used for the treatment of various cancers. It belongs to a class of drugs called angiogenesis inhibitors, which work by targeting and inhibiting the vascular endothelial growth factor (VEGF), a protein responsible for the formation of new blood vessels (angiogenesis). By blocking VEGF, Bevmy reduces the blood supply to the tumor, slowing down its growth and potentially shrinking it.

Abevmy is typically used in combination with other chemotherapy drugs to treat specific cancers. The drug is administered intravenously under the supervision of a healthcare professional, usually in a clinical or hospital setting.

Indications: Abevmy is indicated for the treatment of the following conditions:

• Metastatic Colorectal Cancer (mCRC): In combination with chemotherapy for the treatment of patients with metastatic colorectal cancer.

• Non-Small Cell Lung Cancer (NSCLC): In combination with chemotherapy for the treatment of patients with advanced or metastatic non-small cell lung cancer.

• Renal Cell Carcinoma (RCC): For the treatment of patients with advanced renal cell carcinoma, often in combination with other medications.

• Glioblastoma: For the treatment of patients with glioblastoma that has progressed after prior therapy.

• Ovarian Cancer: In combination with chemotherapy for the treatment of patients with ovarian cancer.

• Cervical Cancer: In combination with chemotherapy for the treatment of persistent, recurrent, or metastatic cervical cancer.

Mechanism of Action: Bevacizumab, the active ingredient in Abevmy, is a humanized monoclonal antibody that binds to VEGF, preventing it from interacting with its receptors on the surface of endothelial cells. This inhibits the process of angiogenesis, which tumors rely on to develop their own blood supply for growth and metastasis. By disrupting this process, Abevmy effectively limits the tumor's ability to receive nutrients and oxygen, leading to reduced tumor size and spread.

Dosage and Administration: Abevmy is administered intravenously by a healthcare provider. The dosing schedule depends on the specific cancer being treated and the regimen being followed, but it is often given once every 2 or 3 weeks. The dose is typically based on the patient’s body surface area and the specific cancer treatment protocol.

Side Effects: Common side effects may include:

• High blood pressure

• Fatigue

• Diarrhea

• Decreased appetite

• Headache

• Abdominal pain

• Bleeding or bruising easily

Serious side effects include:

• Gastrointestinal perforation (hole in the intestine)

• Arterial thromboembolic events (e.g., heart attack, stroke)

• Severe bleeding

• Wound healing complications

• Hypertensive crisis

Patients should inform their doctor of any medical conditions or medications they are currently taking, as there may be interactions or contraindications with other treatments.

Precautions: Before receiving Abevmy, patients should be evaluated for any preexisting medical conditions, particularly hypertension, gastrointestinal issues, or any history of bleeding or clotting disorders. Close monitoring during treatment is required to manage side effects like hypertension, bleeding, or impaired wound healing.

Rolimus 10 Tablets - Product Description

Rolimus 10 is a medication containing 10 mg of Sirolimus, an immunosuppressant drug that primarily works by inhibiting the immune system to prevent organ rejection after transplants. It is also used to treat various conditions that involve an overactive immune system.

Indications:

• Organ Transplantation: Used to prevent organ rejection in kidney, liver, or heart transplant recipients. Sirolimus suppresses the immune response, helping to avoid transplant rejection.

• Autoimmune Diseases: It can be prescribed for certain conditions like systemic lupus erythematosus or other autoimmune diseases, though this use is off-label.

• Cancer Treatment: Sometimes used for certain cancers, as Sirolimus has shown effectiveness in slowing down cancer cell growth.

• Tuberous Sclerosis Complex (TSC): Used to manage TSC, a genetic condition that leads to non-cancerous tumor growth in various organs.

Mechanism of Action:

Sirolimus works by inhibiting the activation of T-cells, which are a key component of the immune response. It does this by binding to an intracellular protein called FKBP-12, forming a complex that inhibits mTOR (mammalian target of rapamycin), a protein responsible for cell growth and division. By blocking mTOR, Rolimus prevents T-cell proliferation, suppressing immune responses that could lead to transplant rejection or unwanted tissue growth in conditions like TSC.

Dosage:

• The dosage of Rolimus varies based on the condition being treated, the patient’s response, and any potential interactions with other medications.

• Typically, the starting dose in transplant patients is around 6 mg to 12 mg, followed by a maintenance dose that is carefully adjusted to ensure adequate blood levels without causing toxicity.

Side Effects:

Common side effects of Rolimus may include:

• Infections: Due to the suppression of the immune system, patients may be more prone to infections.

• Elevated Blood Lipids: Patients may experience higher cholesterol or triglyceride levels.

• Mouth Ulcers: Sores or ulcers in the mouth are a frequent side effect.

• Kidney Issues: Kidney function should be monitored regularly as Sirolimus can affect renal function.

• Liver Issues: Liver function may also be impacted, requiring periodic liver function tests.

• High Blood Pressure: Some patients may experience an increase in blood pressure.

• Gastrointestinal Symptoms: Nausea, vomiting, diarrhea, or abdominal discomfort may occur.

Warnings & Precautions:

• Allergic Reactions: If you have a history of allergies to Sirolimus or related drugs, consult your doctor before use.

• Pregnancy & Breastfeeding: The use of Rolimus during pregnancy or breastfeeding should be avoided unless absolutely necessary, as it may harm the fetus or infant.

• Drug Interactions: Rolimus can interact with several medications, including other immunosuppressants, antifungals, and antibiotics. Always inform your doctor about any other medications you're taking.

• Kidney & Liver Function: Regular monitoring of kidney and liver functions is essential.

Storage:

Store Rolimus tablets at room temperature (between 15°C to 30°C), away from moisture and heat. Keep out of reach of children.

Note: Always use Rolimus under the guidance and supervision of a healthcare professional. Never self-medicate, as incorrect dosage or use may cause serious health issues.

Geftinat Gefitinib 250 mg Tablets – Comprehensive Description

Brand Name: Geftinat
Generic Name: Gefitinib
Strength: 250 mg
Dosage Form: Oral Tablet
Therapeutic Class: Tyrosine Kinase Inhibitor (TKI); Antineoplastic Agent
Manufacturer: Natco Pharma Ltd. (India)

Overview:

Geftinat Gefitinib 250 mg Tablet is an oral anticancer medication used in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with specific mutations in the epidermal growth factor receptor (EGFR) gene. Gefitinib is a tyrosine kinase inhibitor (TKI) that selectively targets the EGFR pathway, which is commonly overactive in certain types of cancer.

 

Geftinat is commonly prescribed as first-line therapy in patients with advanced or metastatic NSCLC who have tested positive for EGFR mutations. By blocking the EGFR signaling pathway, it helps to inhibit tumor growth, slow disease progression, and improve survival outcomes in suitable patients.

Precautions and Warnings:

• Interstitial Lung Disease (ILD): Rare but serious and potentially fatal. Monitor patients for signs of respiratory symptoms (dyspnea, cough, fever).

• Hepatotoxicity: Elevations in liver enzymes have been reported; monitor liver function tests regularly.

• Ocular Disorders: Reports of keratitis and dry eye; patients should report vision changes.

• Gastrointestinal Perforation: Though rare, cases have been reported.

• Diarrhea: A common side effect; monitor for dehydration or electrolyte imbalance.

• Use with caution in patients with severe hepatic or renal impairment.

Adverse Effects:

Common Side Effects:

• Diarrhea

• Rash and acneiform eruptions

• Nausea and vomiting

• Anorexia

• Fatigue

• Dry skin and itching

Less Common/Serious Effects:

 

• Interstitial lung disease

• Liver enzyme elevations

• Ocular toxicity (e.g., conjunctivitis, keratitis)

• Gastrointestinal bleeding or perforation

Drug Interactions:

• CYP3A4 inhibitors/inducers: Gefitinib is metabolized by CYP3A4. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) may reduce efficacy, while inhibitors (e.g., ketoconazole) may increase toxicity.

• Proton pump inhibitors, H2 antagonists, and antacids may reduce absorption due to increased gastric pH. Separate dosing is recommended.

• Warfarin: Increased risk of bleeding; monitor INR closely if co-administered.

Use in Special Populations:

• Pregnancy Category D: May cause fetal harm. Not recommended during pregnancy. Effective contraception should be used.

• Lactation: Discontinue breastfeeding while on treatment.

• Pediatrics: Not approved for use in children.

• Geriatrics: No dose adjustment required solely on the basis of age.

Storage Instructions:

• Store at a temperature between 15°C to 30°C.

• Protect from moisture and heat. Keep in original packaging until use.

• Keep out of reach of children.